Friday, January 20, 2023, San Francisco, California, 6:00 PM – 7:30 PM Pacific Time (9:00 PM – 10:30 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Hepatobiliary Cancers

Part 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Richard S Finn, MD
Professor, Department of Medicine, Division
of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Stanford Cancer Center
Associate Professor
Stanford University School of Medicine
Palo Alto, California


Professor Arndt Vogel, MD
Managing Senior Consultant
Department of Gastroenterology, Hepatology
and Endocrinology
Hannover Medical School
Hannover, Germany

Moderator
Robin K (Katie) Kelley, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF)
San Francisco, California


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.
Program Schedule — Pacific Time
5:30 PM – 6:00 PM — Registration and Dinner Buffet
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn

  • Long-term findings from the Phase III IMbrave150 study comparing first-line atezolizumab/ bevacizumab to sorafenib for advanced unresectable HCC; patient selection for atezolizumab/ bevacizumab
  • Design, eligibility criteria and key endpoints of the Phase III HIMALAYA trial evaluating durvalumab/ tremelimumab or durvalumab alone versus sorafenib as first-line treatment for unresectable advanced HCC
  • Achievement of an overall survival advantage and other key efficacy outcomes with durvalumab/ tremelimumab in the HIMALAYA trial; recent FDA approval and current clinical role
  • Mechanism of action of tislelizumab; similarities and differences with commercially available anti-PD-1/PD-L1 antibodies
  • Available results from the Phase III RATIONALE 301 trial comparing tislelizumab to sorafenib as first-line treatment for advanced unresectable HCC; potential clinical role
  • Current clinical utility of tyrosine kinase inhibitor (TKI) monotherapy as first-line treatment for unresectable HCC; recently presented findings demonstrating a potential advantage with lenvatinib compared to atezolizumab/bevacizumab for nonviral disease

MODULE 2: Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley

  • Factors in the selection and sequencing of treatment for patients with advanced HCC whose disease has progressed on first and consecutive lines of therapy
  • Role of multitargeted TKIs approved in the first-line setting (eg, sorafenib, lenvatinib) among patients with relapsed disease
  • Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) among patients with progressive HCC
  • Results from the Phase III KEYNOTE-394 trial and other pivotal studies examining the role of single-agent immune checkpoint inhibitors for relapsed/refractory HCC
  • Key findings with anti-PD-1/PD-L1 and anti-CTLA-4 combination regimens for patients with progressive HCC
  • Other promising agents and strategies currently under investigation for HCC

MODULE 3: Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel

  • Historical approaches to up-front management of advanced BTCs; disease- and patient-specific factors in selecting therapy
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III TOPAZ-1 trial evaluating durvalumab in combination with chemotherapy as first-line treatment for advanced BTCs
  • Major efficacy and safety findings with the addition of durvalumab to first-line chemotherapy in the TOPAZ-1 trial; FDA approval of up-front durvalumab and implications for clinical practice
  • Early results with and ongoing Phase III evaluation of cisplatin/gemcitabine combined with other anti-PD-1/PD-L1 antibodies (eg, pembrolizumab, atezolizumab) as first-line treatment for advanced BTCs
  • Other research efforts investigating immune checkpoint inhibitors alone or in combination with other systemic therapies for advanced BTCs

MODULE 4: Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal

  • Spectrum and frequency of molecular alterations in cholangiocarcinoma and other BTCs; optimal timing and type of genomic analysis to identify actionable abnormalities
  • Principal findings with pemigatinib, infigratinib and futibatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements
  • Published outcomes from the Phase III ClarIDHy study of ivosidenib for cholangiocarcinoma with an IDH1 mutation; FDA approval and optimal incorporation into clinical practice
  • Ongoing research evaluating targeted therapies (eg, FGFR inhibitors, ivosidenib) for patients with newly diagnosed cholangiocarcinoma
  • Efficacy and safety of trastuzumab deruxtecan among patients with HER2-positive and HER2-low BTCs in the Phase II HERB study
  • Emerging results from the pivotal Phase IIb HERIZON-BTC-01 trial investigating the novel HER2-targeted bispecific antibody zanidatamab as monotherapy for previously treated HER2-amplified and HER2-expressing BTCs
  • Other promising biomarker-based strategies for patients with advanced BTCs

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC).
  • Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these can be optimally integrated into the clinical care of patients.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Evaluate available data documenting the efficacy of anti-PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers, and consider the role of this therapeutic strategy.
  • Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biologic rationale for efforts to exploit documented molecular abnormalities in these diseases.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into the clinical management algorithm.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and refer eligible patients for trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Finn — Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research (to Institution): Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc; Speaker’s Bureau: Genentech, a member of the Roche Group. Dr Goyal — Advisory Board and Consulting Agreements: Alentis Therapeutics AG, Black Diamond Therapeutics Inc, Exelixis Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Incyte Corporation, Kinnate Biopharma, Merck, QED Therapeutics, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Prof Vogel — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, GlaxoSmithKline, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.

MODERATOR — Robin K (Katie) Kelley, MD – Advisory Board: Kinnate Biopharma; Advisory Board or Steering Committee (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Kinnate Biopharma, Merck; Research Funding to Institution: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Uncompensated Service on IDMC: Genentech, a member of the Roche Group, Merck.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 PM PST on Friday, January 20th. If you are interested in attending, please visit our registration desk located outside the Gold Gate Ballroom – Salon A (B2 Level) of the San Francisco Marriott Marquis hotel (780 Mission Street) within walking distance of the Moscone Convention Center (2 street blocks).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the 2023 ASCO GI Symposium.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not official events of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.